These signatures also point to the identification of potential therapeutic targets to be considered for development in adjuvant RCC, such as Mer proto-oncogene tyrosine kinase (MERTK) and Tryptophan 2,3 dioxygenase (TDO2). Here, TDO2 is linked to renal cell carcinoma.